Belimumab concentration measurements using a homologous anti-idiotype immunoassay

Floris C Loeff; Ioannis Parodis; Tomas Walhelm; Andreas Jönsen; Dionysis Nikolopoulos; Christopher Sjöwall; Anders A Bengtsson; Dorien Kos; Astrid van Leeuwen; Bryan van den Broek; Lisanne Dijk; Jorn Jeremiasse; Birgit S Blomjous; Alexandre E Voskuyl; Gerrit Jan Wolbink; Irene E M Bultink; Theo Rispens

doi:10.1016/j.jim.2024.113717

Belimumab concentration measurements using a homologous anti-idiotype immunoassay

J Immunol Methods. 2024 Sep:532:113717. doi: 10.1016/j.jim.2024.113717. Epub 2024 Jul 2.

Authors

Floris C Loeff¹, Ioannis Parodis², Tomas Walhelm³, Andreas Jönsen⁴, Dionysis Nikolopoulos⁵, Christopher Sjöwall³, Anders A Bengtsson⁴, Dorien Kos⁶, Astrid van Leeuwen¹, Bryan van den Broek¹, Lisanne Dijk¹, Jorn Jeremiasse¹, Birgit S Blomjous⁷, Alexandre E Voskuyl⁷, Gerrit Jan Wolbink⁸, Irene E M Bultink⁷, Theo Rispens⁹

Affiliations

¹ Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands.
² Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden; Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
³ Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden.
⁴ Department of Clinical Sciences Lund, Rheumatology, Lund University, Skåne University Hospital, Lund, Sweden.
⁵ Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
⁶ Sanquin Reagents B.V., Amsterdam, the Netherlands.
⁷ Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Center, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
⁸ Amsterdam Rheumatology and immunology Center|Reade, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
⁹ Biologics Laboratory, Sanquin Diagnostic Services, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. Electronic address: [email protected].

PMID: 38960066
DOI: 10.1016/j.jim.2024.113717

Abstract

Monitoring belimumab concentrations in patients can be a valuable tool for assessing treatment response and for personalizing drug doses. Various assay formats may be used to measure concentrations of therapeutic monoclonal antibodies. A particularly useful format involves the use of anti-idiotype monoclonal antibodies, selected to be highly specific to the antibody of interest. Here, we describe the development of a specific, high-affinity anti-idiotype antibody to belimumab, and the application of this antibody in a homologous sandwich ELISA to measure belimumab concentrations.

Keywords: Anti-idiotype antibodies; Belimumab; PK/ADA assays; Rabbit monoclonal antibodies.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antibodies, Anti-Idiotypic* / immunology
Antibodies, Monoclonal, Humanized* / immunology
Antibodies, Monoclonal, Humanized* / therapeutic use
Drug Monitoring* / methods
Enzyme-Linked Immunosorbent Assay* / methods
Humans
Immunosuppressive Agents / blood

Substances

belimumab
Antibodies, Monoclonal, Humanized
Antibodies, Anti-Idiotypic
Immunosuppressive Agents